BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 34462698)

  • 1. The Potential of Glioblastoma Patient Symptoms to Diagnose and Predict Survival.
    Mrowczynski OD; Yang AL; Liao J; Rizk E
    Cureus; 2021 Jul; 13(7):e16675. PubMed ID: 34462698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The predictive potential of hyponatremia for glioblastoma patient survival.
    Mrowczynski OD; Bourcier AJ; Liao J; Langan ST; Specht CS; Rizk EB
    J Neurooncol; 2018 May; 138(1):99-104. PubMed ID: 29372493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
    Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
    Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1
    Cai HQ; Wang PF; Zhang HP; Cheng ZJ; Li SW; He J; Zhang Y; Hao JJ; Wang MR; Yan CX; Wan JH
    J Clin Pathol; 2018 Aug; 71(8):702-707. PubMed ID: 29550762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. H3K27M, IDH1, and ATRX expression in pediatric GBM and their clinical and prognostic significance.
    Uppar AM; Sugur H; Prabhuraj AR; Rao MB; Devi BI; Sampath S; Arivazhagan A; Santosh V
    Childs Nerv Syst; 2019 Sep; 35(9):1537-1545. PubMed ID: 31152217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of IDH1, ATRX and WT-1 mutations in glioblastoma.
    Gülten G; Yalçın N; Baltalarlı B; Doğu G; Acar F; Doğruel Y
    Pol J Pathol; 2020; 71(2):127-137. PubMed ID: 32729303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma.
    Schiffgens S; Wilkens L; Brandes AA; Meier T; Franceschi E; Ermani M; Hartmann C; Sandalcioglu IE; Dumitru CA
    Oncotarget; 2016 Aug; 7(34):55169-55180. PubMed ID: 27409829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential Role of Methylation Marker in Glioma Supporting Clinical Decisions.
    Roszkowski K; Furtak J; Zurawski B; Szylberg T; Lewandowska MA
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical Analysis of ATRX, IDH1 and p53 in Glioblastoma and Their Correlations with Patient Survival.
    Chaurasia A; Park SH; Seo JW; Park CK
    J Korean Med Sci; 2016 Aug; 31(8):1208-14. PubMed ID: 27478330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival of glioblastoma patients related to presenting symptoms, brain site and treatment variables.
    Yuile P; Dent O; Cook R; Biggs M; Little N
    J Clin Neurosci; 2006 Aug; 13(7):747-51. PubMed ID: 16908158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study.
    Pinson H; Hallaert G; Van der Meulen J; Dedeurwaerdere F; Vanhauwaert D; Van den Broecke C; Van Dorpe J; Van Roost D; Kalala JP; Boterberg T
    J Neurooncol; 2020 Jan; 146(1):55-62. PubMed ID: 31701343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
    Weller M; Butowski N; Tran DD; Recht LD; Lim M; Hirte H; Ashby L; Mechtler L; Goldlust SA; Iwamoto F; Drappatz J; O'Rourke DM; Wong M; Hamilton MG; Finocchiaro G; Perry J; Wick W; Green J; He Y; Turner CD; Yellin MJ; Keler T; Davis TA; Stupp R; Sampson JH;
    Lancet Oncol; 2017 Oct; 18(10):1373-1385. PubMed ID: 28844499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Molecular and Imaging Biomarkers in Primary Glioblastoma.
    Bosnyák E; Michelhaugh SK; Klinger NV; Kamson DO; Barger GR; Mittal S; Juhász C
    Clin Nucl Med; 2017 May; 42(5):341-347. PubMed ID: 28195901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
    Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
    Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009.
    Gramatzki D; Dehler S; Rushing EJ; Zaugg K; Hofer S; Yonekawa Y; Bertalanffy H; Valavanis A; Korol D; Rohrmann S; Pless M; Oberle J; Roth P; Ohgaki H; Weller M
    Cancer; 2016 Jul; 122(14):2206-15. PubMed ID: 27088883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors in progressive high-grade glial tumors treated with systemic approach: A single center experience.
    Alan O; Telli TA; Tuylu TB; Arikan R; Demircan NC; Ercelep O; Kaya S; Babacan NA; Atasoy BM; Bozkurt S; Bayri Y; Gul D; Ekinci G; Ziyal I; Dane F; Yumuk PF
    J Oncol Pharm Pract; 2021 Mar; 27(2):329-339. PubMed ID: 32349641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term survival after glioblastoma resection: hope despite poor prognosis factors.
    Costa E; Lawson TM; Lelotte J; Fomekong E; Vaz RG; Renard L; Whenham N; Raftopoulos C
    J Neurosurg Sci; 2019 Jun; 63(3):251-257. PubMed ID: 29363298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of
    Brandes AA; Franceschi E; Paccapelo A; Tallini G; De Biase D; Ghimenton C; Danieli D; Zunarelli E; Lanza G; Silini EM; Sturiale C; Volpin L; Servadei F; Talacchi A; Fioravanti A; Pia Foschini M; Bartolini S; Pession A; Ermani M
    Oncologist; 2017 Apr; 22(4):432-437. PubMed ID: 28275120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter.
    Kim J; Lee SH; Jang JH; Kim MS; Lee EH; Kim YZ
    J Neurosurg; 2017 May; 126(5):1461-1471. PubMed ID: 27367247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Molecular Markers in Glioblastoma-Benefits of Liquid Biopsy.
    Birkó Z; Nagy B; Klekner Á; Virga J
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33053907
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.